Side effects and contraindications of Ripotinib

Repotrectinib (Repotrectinib) is a new generation of targeted tyrosine kinase inhibitors (TKI). It is mainly used for the treatment of ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It has significant advantages in molecular target accuracy and inhibition of drug-resistant mutations. However, like other similar targeted drugs, Ripotinib is also accompanied by a certain degree of side effects during the treatment process, which needs to be scientifically evaluated and managed according to the individual patient's condition.

Common side effects include changes in taste (such as food becoming bitter or tasteless), dizziness, fatigue, nausea, constipation, joint pain, and muscle weakness. Most of these reactions are mild to moderate and can be gradually adapted during treatment or relieved by supportive care. However, for some patients, certain adverse reactions may have a substantial impact on quality of life, and dose adjustments need to be made in a timely manner. Decreased hemoglobin, increased liver enzymes, or slight prolongation of the QTc interval in electrocardiograms have also been observed in clinical practice, suggesting the need to regularly monitor liver function, hemograms, and cardiac electrical status, especially when using other potential QT-prolonging drugs in combination.

In terms of contraindications, Ripotinib is not recommended for use in patients with known allergies to the active ingredients of the drug. At the same time, pregnant and lactating women should avoid using this drug as it may have potential effects on fetal or infant development. Animal studies suggest that the drug may be embryotoxic, so women of childbearing age should use effective contraception while taking the drug and continue for at least several weeks after stopping the drug. In addition, for patients with severe hepatic insufficiency or active infection, the metabolism and toxicity of repotinib may be aggravated, and should be fully evaluated before use.

During the actual medication process, doctors should conduct individualized risk assessments based on the patient's previous treatment history, mutation type, comorbid diseases, and tolerance to ensure that treatment is carried out within a safe range.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html